Patient-Derived Tumor Xenograft Model (PDX) is widely used in the development of new drugs, especially in the selection of patients in clinical trials of target drugs and the study of predictive biomarkers.Animal models such as genome-edited mouse models, patient-derived organoids, and patient-derived xenografts (PDX) have been used to study cancer biology and cancer pathogenesis studies.Medicilon’s research on PDX model includes molecular level genotyping and pharmacological efficacy evaluation service of orthotopic model, promising great prediction for clinical efficacy research.